Long-term safety and efficacy of ramelteon in Japanese patients with chronic insomnia

Sleep Medicine

Volumn 12, Issue 2, 2011, Pages 127-133

  Uchiyama, Makoto ^a   Hamamura, Misako ^b   Kuwano, Tomoaki ^b   Nagata, Hiroshi ^b   Hashimoto, Takamasa ^b   Ogawa, Atsushi ^b   Uchimura, Naohisa ^c  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Insomnia; Japanese patients; Melatonin receptor agonist; Ramelteon; Sleep latency; Tolerability; Total sleep time

Indexed keywords

PLACEBO; RAMELTEON;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC TEST ACCURACY STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; ECZEMA; ENTEROCOLITIS; FEMALE; GASTRITIS; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GOOD CLINICAL PRACTICE; HEPATOBILIARY DISEASE; HUMAN; HYGIENE; INFECTION; INSOMNIA; JAPANESE; LARYNGITIS; LATENT PERIOD; LIVER FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METRORRHAGIA; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL STIFFNESS; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; PYELONEPHRITIS; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN DISEASE; SLEEP TIME; SYNOVITIS; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG TOLERANCE; ENDOCRINE SYSTEM; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INDENES; MALE; MIDDLE AGED; PLACEBOS; RECEPTORS, MELATONIN; RECURRENCE; SINGLE-BLIND METHOD; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME FACTORS; YOUNG ADULT;

EID: 79251634953     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2010.10.006     Document Type: Article

References (21)

1. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007, 3(5 Suppl.):S7-S10.
2. Silber M.H. Clinical practice. chronic insomnia. N Engl J Med 2005, 353:803-810.
3. Kim K., Uchiyama M., Okawa M., Liu X., Ogihara R. An epidemiological study of insomnia among the Japanese general population. Sleep 2000, 23:41-47.
4. Liu X., Uchiyawa M., Kim K., Okawa M., Shibui K., Kudo Y., et al. Sleep loss and daytime sleepiness in the general adult population of Japan. Psychiatry Res 2000, 93:1-11.
5. Ramakrishnan K., Scheid D.C. Treatment options for insomnia. Am Fam Physician 2007, 76:517-526.
6. Mann K., Bauer H., Hiemke C., Röschke J., Wetzel H., Benkert O. Acute, subchronic and discontinuation effects of zopiclone on sleep EEG and nocturnal melatonin secretion. Eur Neuropsychopharmacol 1996, 6:163-168.
7. Hedner J., Yaeche R., Emilien G., Farr I., Salinas E. The Zaleplon clinical investigator study group. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. Int J Geriatr Psychiatry 2000, 15:704-712.
8. Doghramji K. Melatonin and its receptors: a new class of sleep-promoting agents. J Clin Sleep Med 2007, 3(5 Suppl.):S17-S23.
9. Kato K., Hirai K., Nishiyama K., Uchikawa O., Fukatsu K., Ohkawa S., et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005, 48:301-310.
10. Erman M., Seiden D., Zammit G., Sainati S., Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006, 7:17-24.
11. Roth T., Seiden D., Wang-Weigand S., Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007, 23:1005-1014.
12. Zammit G., Erman M., Wang-Weigand S., Sainati S., Zhang J., Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007, 3:495-504.
13. Roth T., Seiden D., Sainati S., Wang-Weigand S., Zhang J., Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006, 7:312-318.
14. Johnson M.W., Suess P.E., Griffiths R.R. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006, 63:1149-1157.
15. Mayer G., Wang-Weigand S., Roth-Schechter B., Lehmann R., Staner C., Partinen M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009, 32:351-360.
16. Richardson G.S., Zammit G., Wang-Weigand S., Zhang J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J Clin Psychiatry 2009, 70:467-476.
17. Uchiyama M., Hamamura M., Kuwano T., Nishiyama H., Nagata H., Uchimura N. Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. Sleep Med 2011, 12:119-126.
18. O'Hanlon J.F. Residual effects on memory and psychomotor performance of zaleplon and other hypnotic drugs. Primary care companion. J Cin Psychiatry 2002, 4(Suppl. 1):38-44.
19. Neubauer D.N. The evolution and development of insomnia pharmacotherapies. J Clin Sleep Med 2007, 3(5 Suppl.):S11-S15.
20. Glass J., Lanctôt K.L., Herrmann N., Sproule B.A., Busto U.E. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005, 331:1169.
21. Richardson G., Wang-Weigand S. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. Hum Psychopharmacol 2009, 24:103-111.